IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Head-To-Head Studies Are Few, But Data Could Change Positioning
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
